Fraudulent data is becoming more common by the submission. So much so that the FDA recently published a press release reminding medical device manufacturers to scrutinize Third-Party Generated Data.” ...
Continuous glucose monitoring (CGM) technology is rapidly expanding beyond Type 1 diabetes to reach a wider demographic, including Type 2 diabetics and wellness users. How manufacturers advancing CGM ...